Page breadcrumb nav

VAERS Report 2156650

Case Report Section

Détails du rapport Vaer

Âge: 29 ans

Genre: Male

Région : Outside US

Patient décédé?
Non
Renseignements sur les vaccins

Nom: COVID19 (COVID19 (MODERNA))

Type : Coronavirus 2019 vaccine

Fabricant: MODERNA

Lot: 000059a


Date de réception du rapport
2022-03-04
Date à laquelle le formulaire est complèté
Date de vaccination
2022-02-11
Date d’apparition
7
Nombre de jours (date d’apparition – date de vaccination)
7
Description de l’événement indésirable

toxic cardiomyopathy; this case was received via the regulatory authority (reference number: gb-mhra-adr 26632578) on 23-feb-2022 and was forwarded to moderna on 23-feb-2022. this regulatory authority case was reported by a consumer and describes the occurrence of toxic cardiomyopathy (toxic cardiomyopathy) in a 29-year-old male patient who received mrna-1273 (moderna covid-19 vaccine) (batch no. 000059a) for travel to foreign country. the patient had no illnesses very healthy. on 11-feb-2022, the patient received first dose of mrna-1273 (moderna covid-19 vaccine) (unknown route) 1 dosage form. on 18-feb-2022, the patient experienced toxic cardiomyopathy (toxic cardiomyopathy) (seriousness criteria hospitalization, disability, medically significant and life threatening). at the time of the report, toxic cardiomyopathy (toxic cardiomyopathy) had not resolved. no concomitant medication was reported. no treatment medication was reported. the patient had a heart attack 6 days after having the moderna vaccine. at 29 years old. the reaction occurred as a result of mistake made in the administration of the vaccine. the doctors confirmed it was due to the vaccine. drug: covid-19 vaccine moderna, reason: travel to foreign country. reaction: toxic cardiomyopathy. the reaction occurred after first dose of vaccine administered. the patient never had a previous problems with blood clotting ot irregular heart rhythm hes 29. the patient never had a clot in his leg (�deep venous thrombosis'), lung (�pulmonary embolism'), brain (stroke) or coronary arteries (heart attack/'myocardial infarction'). the people in patients family not had problems with clots in blood vessels. the patient did not smoke. the patient didn't not experience inflammatory or �autoimmune' diseases, e.g. systemic lupus erythematosus (sle). the patient didn't had any other long-term medical conditions (e.g. diabetes or high cholesterol) or take any regular medication. none other than the moderna vaccine any other vaccine administered recently. the patient did not had any recent surgery or other trauma. the patient condition was still on going. none of the other events or factors which could have contributed to or caused the reaction. at (privacy) hospital the patient was treated. the doctors at the hospital were saying they are seeing increased cases of myocarditis and heart attacks in young people after the vaccine. company comment : this is a regulatory authority case concerning a 29-year-old, male patient with no known disease, non-smoker who experienced the unexpected serious (life-threatening, hospitalization, disability and medically significant according to regulatory authority) aesi event of toxic cardiomyopathy. the event occurred approximately 6 days after the first dose of mrna-1273 vaccine administration which resulted to hospitalization. no reported treatment information. the outcome of the event was not resolved from the time of last observation. the patient's age and gender remains confounders. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report. most recent follow-up information incorporated above includes: on 27-feb-2022: the event medication error was removed and updated the narrative.; sender's comments: this is a regulatory authority case concerning a 29-year-old, male patient with no known disease, non-smoker who experienced the unexpected serious (life-threatening, hospitalization, disability and medically significant according to regulatory authority) aesi event of toxic cardiomyopathy. the event occurred approximately 6 days after the first dose of mrna-1273 vaccine administration which resulted to hospitalization. no reported treatment information. the outcome of the event was not resolved from the time of last observation. the patient's age and gender remains confounders. the benefit-risk relationship of mrna-1273 vaccine is not affected by this report

Données de laboratoire
na
Liste des symptômes
toxic cardiomyopathy
Patient décédé?
Non
Date de décès
N/A
Anomalie congénitale
false
Vaccin administré par :
Unknown
Vaccin acheté par :
Inconnu
Visite d’un patient à l’urgence?
Non
Patient hospitalisé?
Oui
Séjour à l’hôpital
Non
Nombre de jours à l’hôpital
Non spécifié
Invalidité permanente?
Oui
Allergies:
na
Maladie actuelle
na